# Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III

> **NCT03020082** · PHASE3 · COMPLETED · sponsor: **Ascletis Pharmaceuticals Co., Ltd.** · enrollment: 141 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** Danoprevir
- **DRUG:** Ritonavir
- **DRUG:** peginterferon alfa-2a
- **DRUG:** RBV

## Key facts

- **NCT ID:** NCT03020082
- **Lead sponsor:** Ascletis Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2017-05
- **Final completion:** 2017-05
- **Target enrollment:** 141 (ACTUAL)
- **Last updated:** 2021-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03020082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03020082, "Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03020082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*